كورس ال Cardiology كامل صار .. بس ما راح انزله هسه ، لان صراحه ماگدر اعلن وانزل الفيديوهات وانزل تفاصيل وبنفس الوقت اشرح فد شغله جداً متعبه ، فراح اكمل ال nephrology , endocrine,hepatology
وبعدها كلهن اعلن عنهن سويه ، بحيل الله يوم ١٠ بلشهر الجاي او ١٥ ..
فبكيفكم بعد اذا تنتظرون😅

خاف احد يخطر اباله هلسؤال

مثلا لو كلنه سرعة ال depolarisation =100
فأن ال Repolarization = 60
هيج شي

سرعه ال Repolarization تتحدد بل depolarisation

خلصصص الكلام ....

SGLT2 inhibitors.. Class I in HFpEF

مستعدين اليوم نختم ال Normal ECG؟؟
مستعدين للlast dance ??😂
اوعدكم حتصير احلى ختمه ممكن تشوفها بمسلسل ❤️❤️😂

اليوم حتنذكر مفاجئتين بلمحاضره
95% من الطلاب تتوهم بالايسيجي من وراها ومن تجي تحل تتخربط بيها ، وما تعرف وين الخلل ؟؟ اليوم نعرف وين الخلل سويه انشاء الله

اخبث من هيج سؤال ماكو 😂

الواحد بعد ميلحك على guidelines الكارديولجي

2023 ESC GUIDLINES FOR THE MANAGEMENT OF acute Coronary Syndrome
Today 25/8/2023

الجواب من محاضراتنا القادمه في كورس ال endocrine ، انشاء الله يوم ١٠ بلشهر مع بقية الكورسات نعلن عنها..

Highlights of the first day of the 2023 ESC-congres
1- SGLT2 inhibitors are recommended as class I in HF mrEF and HFpEF (dapagliflozin and empagliflozin)
2- there is no change in the strategies of antithrombotic treatment in patients with ACS :
Aspirin + P2Y12 unhibtirs for 12 months flooded by aspirin alone for life long (class I).
3- Surgery is recommended for early Prosthetic valve endocarditis (less than 6 months) with new valve replacement and complete debridement (class IC)
4- ACS management in cancer patients:
Invasive strategy if the life expectancy >6 months
Conservative management if poor prognosis
Antithrombotic therapy according to platelet count
5- SGLT2 inhibitors are recommended as first line treatment ( class I) in type 2 diabetic patients with established ASCVD (to reduce CV risk independent of glucose control , in type2 diabetic patients with HF(to reduce HF hospitalizations ), and in type 2 diabetic patients with CKD (to reduce CV risk and kidney failure risk).
6- Colchicine is the first anti-inflammatory agent (0.5 mg once daily) approved by US FDA and health Canada to reduced the risk of atherothrombotic events in patients with established ASCVD.
7-Colchicine does not significantly reduce perioperative Afib or myocardial injury after non-cardiac surgery (MINS) in patients undergoing major non-cardiac thoracic surgery.
8- Semaglutide (which belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists) improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with HFpEF and obesity (STEP-HFpEF trial)
9- NOACs are finally approved for the treatment of LV thrombus as a complication of ACS( class IIa).
10- DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants
11- complete revascularization should be done either during the index procedure or within 45 days in patients with STEMI (class I).
12- face to an out-hospital cardiac arrest, Primary PCI is recommended as class I when the ECG shows ST segment elevation and class IIIA when the ECG is normal (no routine immediate coronary angiogram).

يرحمكم الله ركزوا على موضوع NSTACS with high risk features
ارجوكمممم يعني هذا تركض بيه لل PCI حاله حال ابو STEMI ، رجاءاً رجاءاً ، والله هواي كيسات NSTACS ما يتم التعامل الصحيح وياهم ..

high risk features
Heamodynamic instability
life threatening arrhythmia
refractory ischemiac pain
AHF
mechanical complication
STEMI equivalents
GRACE score >140
dynamic ST change
dynamic troponin change